and inhibitors that modulate RNA splicing pathways in hematological malignancies. Its activities encompass drug discovery, chemical design, and execution of early-stage clinical trials that assess safety, pharmacology and potential therapeutic effects. BlossomHill Therapeutics works with scientific and clinical teams to evaluate experimental outcomes and refine molecule profiles for progression through clinical study stages. The company also publishes findings from ongoing trials and presents research data to scientific audiences to support understanding of its therapeutic candidates.